[Influence of underlying disease and immunosuppression on the immunocompetence in inflammatory rheumatic diseases].
Einfluss von Grunderkrankung und Immunsuppression auf die Immunkompetenz bei entzündlich rheumatischen Erkrankungen.
Infection risk
Morbidity
Mortality
Risk assessment
Treatment decision
Journal
Zeitschrift fur Rheumatologie
ISSN: 1435-1250
Titre abrégé: Z Rheumatol
Pays: Germany
ID NLM: 0414162
Informations de publication
Date de publication:
29 Aug 2023
29 Aug 2023
Historique:
accepted:
04
06
2023
medline:
30
8
2023
pubmed:
30
8
2023
entrez:
29
8
2023
Statut:
aheadofprint
Résumé
Patients with inflammatory rheumatic diseases have a higher risk of infections in comparison to the general population. For this patient group, in addition to cardiovascular diseases, infections play an important role with respect to morbidity and mortality. Even if it is difficult to make concrete statements with respect to individual diseases, it can be assumed that there is a lower risk of infections in inflammatory joint diseases in comparison to connective tissue diseases and vasculitides. The increased risk of infections is determined by multiple factors, whereby the underlying factors are classified into three main categories: patient-related factors (age, comorbidities, lifestyle), disease-related factors (immunological dysfunction as part of the disease pathophysiology) and drug-related factors (type and dosage of the immunosuppression and/or immunomodulation). An improved understanding of the complexity of these associations enables the optimization of treatment and disease control taking the individual risk factors into account, with the aim of a significant reduction in the risk of infections. Patient:innen mit entzündlich rheumatischen Erkrankungen weisen ein höheres Infektionsrisiko im Vergleich zur Allgemeinbevölkerung auf. Für diese Patientengruppe spielen Infektionen neben kardiovaskulären Erkrankungen eine wesentliche Rolle hinsichtlich Morbidität und Mortalität. Auch wenn es schwierig ist, hierzu sichere Aussagen in Bezug auf einzelne Erkrankungen zu treffen, ist von einem geringeren Infektionsrisiko bei entzündlichen Gelenkerkrankungen im Vergleich zu Kollagenosen und Vaskulitiden auszugehen. Das erhöhte Infektionsrisiko ist multifaktoriell bedingt, wobei die zugrunde liegenden Faktoren sich in 3 Hauptkategorien auffächern: patientenbezogene Faktoren (Alter, Komorbiditäten, Livestyle), krankheitsbezogene Faktoren (immunologische Dysfunktion als Teil der Krankheitspathophysiologie) und medikamentenbezogene Faktoren (Art und Dosis der Immunsupression/Immunmodulation). Ein besseres Verständnis für die Komplexität dieser Zusammenhänge ermöglicht die Optimierung von Therapie und Krankheitskontrolle unter Berücksichtigung der individuellen Risikofaktoren mit dem Ziel einer signifikanten Reduktion des Infektionsrisikos.
Autres résumés
Type: Publisher
(ger)
Patient:innen mit entzündlich rheumatischen Erkrankungen weisen ein höheres Infektionsrisiko im Vergleich zur Allgemeinbevölkerung auf. Für diese Patientengruppe spielen Infektionen neben kardiovaskulären Erkrankungen eine wesentliche Rolle hinsichtlich Morbidität und Mortalität. Auch wenn es schwierig ist, hierzu sichere Aussagen in Bezug auf einzelne Erkrankungen zu treffen, ist von einem geringeren Infektionsrisiko bei entzündlichen Gelenkerkrankungen im Vergleich zu Kollagenosen und Vaskulitiden auszugehen. Das erhöhte Infektionsrisiko ist multifaktoriell bedingt, wobei die zugrunde liegenden Faktoren sich in 3 Hauptkategorien auffächern: patientenbezogene Faktoren (Alter, Komorbiditäten, Livestyle), krankheitsbezogene Faktoren (immunologische Dysfunktion als Teil der Krankheitspathophysiologie) und medikamentenbezogene Faktoren (Art und Dosis der Immunsupression/Immunmodulation). Ein besseres Verständnis für die Komplexität dieser Zusammenhänge ermöglicht die Optimierung von Therapie und Krankheitskontrolle unter Berücksichtigung der individuellen Risikofaktoren mit dem Ziel einer signifikanten Reduktion des Infektionsrisikos.
Identifiants
pubmed: 37644129
doi: 10.1007/s00393-023-01408-4
pii: 10.1007/s00393-023-01408-4
doi:
Types de publication
English Abstract
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
Références
Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46(9):2287–2293
pubmed: 12355475
doi: 10.1002/art.10524
Pego-Reigosa JM, Nicholson L, Pooley N, Langham S, Embleton N, Marjenberg Z et al (2021) The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis. Rheumatolopgy (Oxford) 60(1):60–72
doi: 10.1093/rheumatology/keaa478
Sarica SH, Dhaun N, Sznajd J, Harvie J, McLaren J, McGeoch L et al (2020) Characterizing infection in anti-neutrophil cytoplasmic antibody-associated vasculitis: results from a longitudinal, matched-cohort data linkage study. Rheumatology (Oxford) 59(10):3014–3022
pubmed: 32159801
doi: 10.1093/rheumatology/keaa070
Cobb S, Anderson F, Bauer W (1953) Length of life and cause of death in rheumatoid arthritis. N Engl J Med 249(14):553–556
pubmed: 13087647
doi: 10.1056/NEJM195310012491402
Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C et al (2011) Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70(3):488–494
pubmed: 21109517
doi: 10.1136/ard.2010.137778
Rathmann J, Jayne D, Segelmark M, Jönsson G, Mohammad AJ (2021) Incidence and predictors of severe infections in ANCA-associated vasculitis: a population-based cohort study. Rheumatology (Oxford) 60(6):2745–2754
pubmed: 33253372
doi: 10.1093/rheumatology/keaa699
Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A et al (2011) Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 70(11):1914–1920
pubmed: 21791449
doi: 10.1136/ard.2011.151043
Hohensinner PJ, Goronzy JJ, Weyand CM (2011) Telomere dysfunction, autoimmunity and aging. Aging Dis 2(6):524–537
pubmed: 22396899
pmcid: 3295061
Frenz T, Grabski E, Buschjäger D, Vaas LAI, Burgdorf N, Schmidt RE et al (2016) CD4+ T cells in patients with chronic inflammatory rheumatic disorders show distinct levels of exhaustion. J Allergy Clin Immunol 138(2):586–589.e10
pubmed: 27264455
doi: 10.1016/j.jaci.2016.04.013
Weißenberg SY, Szelinski F, Schrezenmeier E, Stefanski AL, Wiedemann A, Rincon-Arevalo H et al (2019) Identification and characterization of post-activated B cells in systemic autoimmune diseases. Front Immunol 10:2136
pubmed: 31616406
pmcid: 6768969
doi: 10.3389/fimmu.2019.02136
Truedsson L, Bengtsson AA, Sturfelt G (2007) Complement deficiencies and systemic lupus erythematosus. Autoimmunity 40(8):560–566
pubmed: 18075790
doi: 10.1080/08916930701510673
Torrente-Segarra V, Salman-Monte TC, Rúa-Figueroa Í, Del Campo V, López-Longo FJ, Galindo-Izquierdo M et al (2020) Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER). Semin Arthritis Rheum 50(4):657–662
pubmed: 32505871
doi: 10.1016/j.semarthrit.2020.05.016
Mehta B, Pedro S, Ozen G, Kalil A, Wolfe F, Mikuls T et al (2019) Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open 5(1):e935
pubmed: 31245055
pmcid: 6560658
doi: 10.1136/rmdopen-2019-000935
Accortt NA, Lesperance T, Liu M, Rebello S, Trivedi M, Li Y et al (2018) Impact of sustained remission on the risk of serious infection in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 70(5):679–684
pubmed: 28960869
doi: 10.1002/acr.23426
Lee KA, Flores RR, Jang IH, Saathoff A, Robbins PD (2022) Immune senescence, immunosenescence and aging. Front Aging 3:900028
pubmed: 35821850
pmcid: 9261375
doi: 10.3389/fragi.2022.900028
Wagner UG, Koetz K, Weyand CM, Goronzy JJ (1998) Perturbation of the T cell repertoire in rheumatoid arthritis. Proc Natl Acad Sci U S A 95(24):14447–14452
pubmed: 9826720
pmcid: 24393
doi: 10.1073/pnas.95.24.14447
Wedderburn LR, Maini MK, Patel A, Beverley PC, Woo P (1999) Molecular fingerprinting reveals non-overlapping T cell oligoclonality between an inflamed site and peripheral blood. Int Immunol 11(4):535–543
pubmed: 10323206
doi: 10.1093/intimm/11.4.535
Fraser P, Lu L, DeCeulaer K, Schur P, Fici D, Awdeh Z et al (1999) CD4 TCRBV CDR3 analysis in prevalent SLE cases from two ethnic groups. Lupus 8(4):311–319
pubmed: 10413211
doi: 10.1191/096120399678847902
Shigematsu M, Masuda H (1996) Usage of T cell receptor (TCR) V beta gene in ulcerative colitis. J Clin Lab Immunol 48(5):177–186
pubmed: 9394241
Direskeneli H, Eksioglu-Demiralp E, Kibaroglu A, Yavuz S, Ergun T, Akoglu T (1999) Oligoclonal T cell expansions in patients with Behcet’s disease. Clin Exp Immunol 117(1):166–170
pubmed: 10403931
pmcid: 1905484
doi: 10.1046/j.1365-2249.1999.00931.x
Vallejo AN, Weyand CM, Goronzy JJ (2004) T‑cell senescence: a culprit of immune abnormalities in chronic inflammation and persistent infection. Trends Mol Med 10(3):119–124
pubmed: 15102354
doi: 10.1016/j.molmed.2004.01.002
Strioga M, Pasukoniene V, Characiejus D (2011) CD8+ CD28− and CD8+ CD57+ T cells and their role in health and disease. Immunology 134(1):17–32
pubmed: 21711350
pmcid: 3173691
doi: 10.1111/j.1365-2567.2011.03470.x
Scarsi M, Ziglioli T, Airò P (2010) Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response. J Rheumatol 37(5):911–916
pubmed: 20231200
doi: 10.3899/jrheum.091176
Aiello A, Farzaneh F, Candore G, Caruso C, Davinelli S, Gambino CM et al (2019) Immunosenescence and its hallmarks: how to oppose aging strategically? A review of potential options for therapeutic intervention. Front Immunol 10:2247
pubmed: 31608061
pmcid: 6773825
doi: 10.3389/fimmu.2019.02247
Dörner T, Giesecke C, Lipsky PE (2011) Mechanisms of B cell autoimmunity in SLE. Arthritis Res Ther 13(5):243
pubmed: 22078750
pmcid: 3308063
doi: 10.1186/ar3433
Sellam J, Rouanet S, Hendel-Chavez H, Abbed K, Sibilia J, Tebib J et al (2011) Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum 63(12):3692–3701
pubmed: 22127692
doi: 10.1002/art.30599
Odler B, Riedl R, Gauckler P, Shin JI, Leierer J, Merkel PA et al (2023) Risk factors for serious infections in ANCA-associated vasculitis. Ann Rheum Dis. https://doi.org/10.1136/ard-2022-223401
doi: 10.1136/ard-2022-223401
pubmed: 36702528
Stefanski AL, Rincon-Arevalo H, Schrezenmeier E, Karberg K, Szelinski F, Ritter J et al (2022) B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab. Arthritis Rheumatol 74(6):934–947
pubmed: 34962360
pmcid: 9011692
doi: 10.1002/art.42060
Gies V, Schickel JN, Jung S, Joublin A, Glauzy S, Knapp AM et al (2018) Impaired TLR9 responses in B cells from patients with systemic lupus erythematosus. JCI Insight. https://doi.org/10.1172/jci.insight.96795
doi: 10.1172/jci.insight.96795
pubmed: 29515028
pmcid: 5922279
McKinney EF, Lee JC, Jayne DR, Lyons PA, Smith KG (2015) T‑cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature 523(7562):612–616
pubmed: 26123020
pmcid: 4623162
doi: 10.1038/nature14468
Stefanski AL, Wiedemann A, Reiter K, Hiepe F, Lino AC, Dörner T (2019) Enhanced programmed death 1 and diminished programmed death ligand 1 up-regulation capacity of post-activated lupus B cells. Arthritis Rheumatol 71(9):1539–1544
pubmed: 30919595
doi: 10.1002/art.40897
Rondaan C, de Haan A, Horst G, Hempel JC, van Leer C, Bos NA et al (2014) Altered cellular and humoral immunity to varicella-zoster virus in patients with autoimmune diseases. Arthritis Rheumatol 66(11):3122–3128
pubmed: 25223407
doi: 10.1002/art.38804
Lima G, Treviño-Tello F, Atisha-Fregoso Y, Llorente L, Fragoso-Loyo H, Jakez-Ocampo J (2021) Exhausted T cells in systemic lupus erythematosus patients in long-standing remission. Clin Exp Immunol 204(3):285–295
pubmed: 33475152
pmcid: 8119791
doi: 10.1111/cei.13577
Capsoni F, Sarzi-Puttini P, Zanella A (2005) Primary and secondary autoimmune neutropenia. Arthritis Res Ther 7(5):208
pubmed: 16207350
pmcid: 1257445
doi: 10.1186/ar1803
Starkebaum G (ed) (2002) Chronic neutropenia associated with autoimmune disease. Seminars in hematology. Elsevier. https://doi.org/10.1053/shem.2002.31918
Cuchacovich R, Gedalia A (2009) Pathophysiology and clinical spectrum of infections in systemic lupus erythematosus. Rheum Dis Clin North Am 35(1):75–93
pubmed: 19480998
doi: 10.1016/j.rdc.2009.03.003
Ren Y, Tang J, Mok M, Chan AW, Wu A, Lau C (2003) Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum 48(10):2888–2897
pubmed: 14558095
doi: 10.1002/art.11237
Tsai C‑Y, Wu T‑H, Yu C‑L, Tsai Y‑Y, Chou C‑T (2002) Decreased IL-12 production by polymorphonuclear leukocytes in patients with active systemic lupus erythematosus. Immunol Invest 31(3–4):177–189
pubmed: 12472178
doi: 10.1081/IMM-120016239
Liu M, Liang S, Zhang C (2021) NK Cells in Autoimmune Diseases: Protective or Pathogenic? Front Immunol. https://doi.org/10.3389/fimmu.2021.624687
doi: 10.3389/fimmu.2021.624687
pubmed: 35754999
pmcid: 8750059
Bosch X, Guilabert A, Pallares L, Cervera R, Ramos-Casals M, Bové A et al (2006) Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus 15(9):584–589
pubmed: 17080913
doi: 10.1177/0961203306071919
Chen T, Wu D, Chen H, Yan W, Yang D, Chen G et al (2020) Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. bmj. https://doi.org/10.1136/bmj.m1091
doi: 10.1136/bmj.m1091
pubmed: 33323388
pmcid: 8009089
Lawson-Tovey S, Hyrich KL, Gossec L, Strangfeld A, Carmona L, Raffeiner B et al (2022) SARS-CoV‑2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis 81(1):145–150
pubmed: 34489305
doi: 10.1136/annrheumdis-2021-221217
Puéchal X, Génin E, Bienvenu T, Le Jeunne C, Dusser DJ (2014) Poor survival in rheumatoid arthritis associated with bronchiectasis: a family-based cohort study. PLoS ONE 9(10):e110066
pubmed: 25310716
pmcid: 4195708
doi: 10.1371/journal.pone.0110066
Abu-Ashour W, Twells L, Valcour J, Randell A, Donnan J, Howse P et al (2017) The association between diabetes mellitus and incident infections: a systematic review and meta-analysis of observational studies. BMJ Open Diabetes Res Care 5(1):e336
pubmed: 28761647
pmcid: 5530269
doi: 10.1136/bmjdrc-2016-000336
Syed-Ahmed M, Narayanan M (2019) Immune dysfunction and risk of infection in chronic kidney disease. Adv Chronic Kidney Dis 26(1):8–15
pubmed: 30876622
doi: 10.1053/j.ackd.2019.01.004
Subesinghe S, Rutherford AI, Byng-Maddick R, Leanne Hyrich K, Benjamin Galloway J (2018) Recurrent serious infections in patients with rheumatoid arthritis—Results from the British Society for Rheumatology Biologics Register. Rheumatology 57(4):651–655
pubmed: 29340619
doi: 10.1093/rheumatology/kex469
Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N et al (2007) Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 66(10):1339–1344
pubmed: 17261532
pmcid: 1994293
doi: 10.1136/ard.2006.062760
Baik I, Curhan GC, Rimm EB, Bendich A, Willett WC, Fawzi WW (2000) A prospective study of age and lifestyle factors in relation to community-acquired pneumonia in US men and women. Arch Intern Med 160(20):3082–3088
pubmed: 11074737
doi: 10.1001/archinte.160.20.3082
Greenberg J, Reed G, Kremer J, Tindall E, Kavanaugh A, Zheng C et al (2010) Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 69(2):380–386
pubmed: 19359261
doi: 10.1136/ard.2008.089276
Kneitz C, Atta J, Burkhardt H (2017) Zytopenien: Anämie, Leukopenie und Thrombopenie. Z Rheumatol 76(Suppl 2):63–74
pubmed: 28971213
doi: 10.1007/s00393-017-0364-7
Dey M, Bechman K, Zhao S, Fragoulis GE, Smith C, Cope A et al (2022) Infection profile of immune-modulatory drugs used in autoimmune diseases: analysis of summary of product characteristic data. RMD Open. https://doi.org/10.1136/rmdopen-2022-002621
doi: 10.1136/rmdopen-2022-002621
pubmed: 36418084
pmcid: 9685189
Rutherford AI, Patarata E, Subesinghe S, Hyrich KL, Galloway JB (2018) Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford) 57(6):997–1001
pubmed: 29529307
doi: 10.1093/rheumatology/key023
Lortholary O, Fernandez-Ruiz M, Baddley JW, Manuel O, Mariette X, Winthrop KL (2020) Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020. Ann Rheum Dis 79(12):1532–1543
pubmed: 32963049
doi: 10.1136/annrheumdis-2020-217092
Fragoulis GE, Nikiphorou E, Dey M, Zhao SS, Courvoisier DS, Arnaud L et al (2022) 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. https://doi.org/10.1136/ard-2022-223335
doi: 10.1136/ard-2022-223335
pubmed: 36328476
Keyßer G (2021) Safety aspects of the treatment with glucocorticoids for rheumatoid arthritis. Z Rheumatol 80(4):295–304
pubmed: 33704557
pmcid: 7948162
doi: 10.1007/s00393-021-00972-x
Wu J, Keeley A, Mallen C, Morgan AW, Pujades-Rodriguez M (2019) Incidence of infections associated with oral glucocorticoid dose in people diagnosed with polymyalgia rheumatica or giant cell arteritis: a cohort study in England. CMAJ 191(25):E680–E688
pubmed: 31235489
pmcid: 6592810
doi: 10.1503/cmaj.190178
Winthrop KL (2012) Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention. Rheum Dis Clin North Am 38(4):727–745
pubmed: 23137579
doi: 10.1016/j.rdc.2012.08.019
Dixon WG, Abrahamowicz M, Beauchamp ME, Ray DW, Bernatsky S, Suissa S et al (2012) Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 71(7):1128–1133
pubmed: 22241902
doi: 10.1136/annrheumdis-2011-200702
Boers M, Hartman L, Opris-Belinski D, Bos R, Kok MR, Da Silva JA et al (2022) Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. Ann Rheum Dis 81(7):925–936
pubmed: 35641125
doi: 10.1136/annrheumdis-2021-221957
Jick SS, Lieberman ES, Rahman MU, Choi HK (2006) Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 55(1):19–26
pubmed: 16463407
doi: 10.1002/art.21705
Winthrop KL, Curtis JR, Lindsey S, Tanaka Y, Yamaoka K, Valdez H et al (2017) Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol 69(10):1960–1968
pubmed: 28845604
pmcid: 5656820
doi: 10.1002/art.40189
Park JW, Curtis JR, Kim MJ, Lee H, Song YW, Lee EB (2019) Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole. Arthritis Res Ther 21(1):207
pubmed: 31521185
pmcid: 6744623
doi: 10.1186/s13075-019-1996-6
Winthrop KL, Baddley JW (2018) Pneumocystis and glucocorticoid use: to prophylax or not to prophylax (and when?); that is the question. Ann Rheum Dis 77(5):631–633
pubmed: 29459427
doi: 10.1136/annrheumdis-2017-212588
Wagner C, Griesel M, Mikolajewska A, Mueller A, Nothacker M, Kley K et al (2021) Systemic corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev 8(8):Cd14963
pubmed: 34396514
Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE (2002) Predictors of infection in rheumatoid arthritis. Arthritis Rheum 46(9):2294–2300
pubmed: 12355476
doi: 10.1002/art.10529
Quach LT, Chang BH, Brophy MT, Soe Thwin S, Hannagan K, O’Dell JR (2017) Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events. Rheumatology (Oxford) 56(3):378–383
pubmed: 27994091
Rúa-Figueroa Í, López-Longo J, Galindo-Izquierdo M, Calvo-Alén J, Del Campo V, Olivé-Marqués A et al (2017) Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. Semin Arthritis Rheum 47(1):38–45
pubmed: 28259425
doi: 10.1016/j.semarthrit.2017.01.010
Rath E, Bonelli M, Duftner C, Gruber J, Mandl P, Moazedi-Furst F et al (2023) National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic DMARDS (disease modifying antirheumatic drugs). Z Rheumatol 82(2):163–174
pubmed: 36342525
doi: 10.1007/s00393-022-01274-6
Desai RJ, Thaler KJ, Mahlknecht P, Gartlehner G, McDonagh MS, Mesgarpour B et al (2016) Comparative risk of harm associated with the use of targeted immunomodulators: a systematic review. Arthritis Care Res (Hoboken) 68(8):1078–1088
pubmed: 26663412
doi: 10.1002/acr.22815
Simon D, Tascilar K, Kleyer A, Fagni F, Krönke G, Meder C et al (2022) Impact of cytokine inhibitor therapy on the prevalence, seroconversion rate, and longevity of the humoral immune response against SARS-CoV‑2 in an unvaccinated cohort. Arthritis Rheumatol 74(5):783–790
pubmed: 34951137
pmcid: 9011429
doi: 10.1002/art.42035
Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, Dougados M et al (2019) Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. BMJ 364:l67
pubmed: 30679233
pmcid: 6344892
doi: 10.1136/bmj.l67
Thietart S, Karras A, Augusto JF, Philipponnet C, Carron PL, Delbrel X et al (2022) Evaluation of rituximab for induction and maintenance therapy in patients 75 years and older with antineutrophil cytoplasmic antibody-associated vasculitis. JAMA Netw Open 5(7):e2220925
pubmed: 35802372
pmcid: 9270693
doi: 10.1001/jamanetworkopen.2022.20925
Henry J, Gottenberg JE, Rouanet S, Pavy S, Sellam J, Tubach F et al (2018) Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection. Rheumatology (Oxford) 57(3):538–547
pubmed: 29267905
doi: 10.1093/rheumatology/kex446
Kronbichler A, Kerschbaum J, Gopaluni S, Tieu J, Alberici F, Jones RB et al (2018) Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 77(10):1440–1447
pubmed: 29950327
doi: 10.1136/annrheumdis-2017-212861
Cornberg M, Sandmann L, Protzer U, Niederau C, Tacke F, Berg T et al (2021) S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik undTherapie der Hepatitis-B-Virusinfektion; Juni2021-(AWMF-Register-Nr.021-11). Z Gastroenterol 59(7):691–776
pubmed: 34255317
doi: 10.1055/a-1498-2512
Arzneimittelkommission der deutschen Ärzteschaft (2018) „Aus der UAW-Datenbank“ – Schwere Immundefekte nach Behandlung mit Rituximab. Dtsch Arztebl Int 115(49):A-2313
Md Yusof MY, Vital EM, McElvenny DM, Hensor EMA, Das S, Dass S et al (2019) Predicting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 71(11):1812–1823
pubmed: 31131994
doi: 10.1002/art.40937
Wijetilleka S, Jayne DR, Mukhtyar C, Ala A, Bright PD, Chinoy H et al (2019) Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases. Rheumatology (Oxford) 58(5):889–896
pubmed: 30590695
doi: 10.1093/rheumatology/key394
Sparks JA, Wallace ZS, Seet AM, Gianfrancesco MA, Izadi Z, Hyrich KL et al (2021) Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis 80(9):1137–1146
pubmed: 34049860
doi: 10.1136/annrheumdis-2021-220418
Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L et al (2021) Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 80(7):930–942
pubmed: 33504483
doi: 10.1136/annrheumdis-2020-219498
Boekel L, Stalman EW, Wieske L, Hooijberg F, van Dam KPJ, Besten YR et al (2022) Breakthrough SARS-CoV‑2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies. Lancet Rheumatol 4(6):e417–e429
pubmed: 35527808
pmcid: 9054068
doi: 10.1016/S2665-9913(22)00102-3
Mathian A, Breillat P, Dorgham K, Bastard P, Charre C, Lhote R et al (2022) Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN‑α. Ann Rheum Dis 81(12):1695–1703
pubmed: 35973806
doi: 10.1136/ard-2022-222549
Chen SK, Liao KP, Liu J, Kim SC (2020) Risk of hospitalized infection and initiation of abatacept versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis: a propensity score-matched cohort study. Arthritis Care Res (Hoboken) 72(1):9–17
pubmed: 30570833
doi: 10.1002/acr.23824
Grøn KL, Arkema EV, Glintborg B, Mehnert F, Østergaard M, Dreyer L et al (2019) Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden. Ann Rheum Dis 78(3):320–327
pubmed: 30612115
doi: 10.1136/annrheumdis-2018-214326
Li X, Andersen KM, Chang HY, Curtis JR, Alexander GC (2020) Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. Ann Rheum Dis 79(2):285–291
pubmed: 31672774
doi: 10.1136/annrheumdis-2019-216102
Jin Y, Lee H, Lee MP, Landon JE, Merola JF, Desai RJ et al (2022) Risk of hospitalization for serious infection after initiation of ustekinumab or other biologics in patients with psoriasis or psoriatic arthritis. Arthritis Care Res (Hoboken) 74(11):1792–1805
pubmed: 33973371
doi: 10.1002/acr.24630
Chen MH, Lee IC, Chen MH, Hou MC, Tsai CY, Huang YH (2021) Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease. Ann Rheum Dis 80(11):1393–1399
pubmed: 34187776
doi: 10.1136/annrheumdis-2021-220774
Cantini F, Nannini C, Niccoli L, Petrone L, Ippolito G, Goletti D (2017) Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics. Mediators Inflamm. https://doi.org/10.1155/2017/8909834
doi: 10.1155/2017/8909834
pubmed: 28659665
pmcid: 5474286
Saunte DM, Mrowietz U, Puig L, Zachariae C (2017) Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol 177(1):47–62
pubmed: 27580411
doi: 10.1111/bjd.15015
Redeker I, Albrecht K, Kekow J, Burmester GR, Braun J, Schäfer M et al (2022) Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. Ann Rheum Dis 81(1):41–47
pubmed: 34321218
doi: 10.1136/annrheumdis-2021-220651
Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386(4):316–326
pubmed: 35081280
doi: 10.1056/NEJMoa2109927
Balanescu A‑R, Citera G, Pascual-Ramos V, Bhatt DL, Connell CA, Gold D et al (2022) Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL surveillance trial. Ann Rheum Dis 81(11):1491–1503
pubmed: 35922124
doi: 10.1136/ard-2022-222405
Nash P, Kerschbaumer A, Dörner T, Dougados M, Fleischmann RM, Geissler K et al (2021) Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis 80(1):71–87
pubmed: 33158881
doi: 10.1136/annrheumdis-2020-218398
Bechman K, Subesinghe S, Norton S, Atzeni F, Galli M, Cope AP et al (2019) A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford) 58(10):1755–1766
pubmed: 30982883
doi: 10.1093/rheumatology/kez087
Mease PJ, Deodhar AA, van der Heijde D, Behrens F, Kivitz AJ, Neal J et al (2022) Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis 81(6):815–822
pubmed: 35241426
doi: 10.1136/annrheumdis-2021-221664
Feldman CH, Marty FM, Winkelmayer WC, Guan H, Franklin JM, Solomon DH et al (2017) Comparative rates of serious infections among patients with systemic lupus erythematosus receiving immunosuppressive medications. Arthritis Rheumatol 69(2):387–397
pubmed: 27589220
pmcid: 5274610
doi: 10.1002/art.39849
Garcia-Vives E, Segarra-Medrano A, Martinez-Valle F, Agraz I, Solans-Laque R (2020) Prevalence and risk factors for major infections in patients with antineutrophil cytoplasmic antibody-associated vasculitis: influence on the disease outcome. J Rheumatol 47(3):407–414
pubmed: 31203229
doi: 10.3899/jrheum.190065